Evidence map›Paper›PMID 14969594›Full record

SynthesisBMC family practice2003

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.

Jayne E Edwards, R Andrew Moore

Open access · goldAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC family practice, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 8 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 8 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pravastatin for lowering lipids.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  2. Pitavastatin for lowering lipids.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  3. Cerivastatin for lowering lipids.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  4. Fluvastatin for lowering lipids.The Cochrane database of systematic reviews · 2018
    Pooled it
  5. Lipid-lowering efficacy of atorvastatin.The Cochrane database of systematic reviews · 2015 · on this map
    Pooled it
  6. Lipid-lowering efficacy of rosuvastatin.The Cochrane database of systematic reviews · 2014 · on this map
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jayne E EdwardsPain Research Unit & Nuffield Department of Anaesthetics, University of Oxford, The Churchill, Headington, Oxford, OX3 7LJ, UK. jayne.edwards@pru.ox.ac.uk
R Andrew Moore
University of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatins alter lipid concentrations. This systematic review determined the efficacy of particular statins, in terms of their ability to alter cholesterol. REVIEW

methodsPubMed, the Cochrane Library, references lists of reports, and reviews were searched (September 2001) for randomised, double blind trials of statins for cholesterol in trials of 12 weeks or longer. Mean change in total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides was calculated using pooled data for particular statins, and for particular doses of a statin. Pre-planned sensitivity analyses were used to determine the effects of initial concentration of total cholesterol, study duration, the effects of major trials, and effects in placebo versus active controlled trials. Information was not collected on adverse events.

resultsDifferent statins at a range of doses reduced total cholesterol by 17-35% and LDL-cholesterol by 24-49% from baseline. Lower doses of statins generally produced less cholesterol lowering, though for most statins in trials of 12 weeks or longer there was at best only a weak relationship between dose and cholesterol reduction. Duration of treatment and baseline total cholesterol concentration did not alter the amount of the benefit attained.

conclusionsStatins are effective medicines and confer benefit to patients in terms of primary and secondary prevention of coronary heart disease. Reductions in total cholesterol of 25% or more and LDL cholesterol of more than 30% were recorded for fixed doses of simvastatin 40 mg, atorvastatin 10 mg, and rosuvastatin 5 mg and 10 mg.

Indexed as

AtorvastatinCholesterolCholesterol, HDLCholesterol, LDLDose-Response Relationship, DrugFatty Acids, MonounsaturatedFemaleFluorobenzenesFluvastatinHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaIndolesLovastatinMaleAtorvastatincerivastatinCholesterolCholesterol, HDLCholesterol, LDLFatty Acids, MonounsaturatedFluorobenzenesFluvastatinHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesLovastatinPravastatinPyridinesPyrimidinesPyrrolesRosuvastatin CalciumSimvastatinSulfonamidesTriglycerides

Identifiers

PMID14969594
PMCPMC317299
OpenAlexW2128840214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.